Regenxbio (RGNX) Operating Leases (2019 - 2025)
Historic Operating Leases for Regenxbio (RGNX) over the last 7 years, with Q3 2025 value amounting to $67.4 million.
- Regenxbio's Operating Leases fell 1166.99% to $67.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.4 million, marking a year-over-year decrease of 1166.99%. This contributed to the annual value of $74.1 million for FY2024, which is 984.04% down from last year.
- Per Regenxbio's latest filing, its Operating Leases stood at $67.4 million for Q3 2025, which was down 1166.99% from $69.6 million recorded in Q2 2025.
- Regenxbio's 5-year Operating Leases high stood at $88.8 million for Q4 2022, and its period low was $67.4 million during Q3 2025.
- Over the past 5 years, Regenxbio's median Operating Leases value was $82.4 million (recorded in 2021), while the average stood at $80.4 million.
- In the last 5 years, Regenxbio's Operating Leases soared by 106278.05% in 2021 and then tumbled by 1166.99% in 2025.
- Over the past 5 years, Regenxbio's Operating Leases (Quarter) stood at $84.9 million in 2021, then increased by 4.56% to $88.8 million in 2022, then dropped by 7.41% to $82.2 million in 2023, then decreased by 9.84% to $74.1 million in 2024, then dropped by 9.04% to $67.4 million in 2025.
- Its Operating Leases was $67.4 million in Q3 2025, compared to $69.6 million in Q2 2025 and $71.9 million in Q1 2025.